MRSA Detection : 6 Hours
Group B Strep Detection : ± 6 Hours
E. coli Detection : 4 Hours
Anthrax Detection : ± 1 Hour
RAPID DETECTION OF VIABLE MICROORGANISMS
NanoLogix® NanoLogix BNP Petri-based sandwiched-membrane kits are simple and reliable rapid test solutions that detect active threat bacteria and other microorganisms 4x - 12x faster than traditional Petri culture technology. NanoLogix FlatPack packaging allows for an extended shelf-life for both our Petri plates and our BNP kits that is frequently more than double today's standard. In ongoing shelf-life tests, NanoLogix Petri plates containing TSA media in FlatPacks® have maintained viability for nutrient and moisture levels for over three years in cold storage and over two years at room temperature (RT), as compared to 3-1/2 months of useable shelf life for competitive products that require refrigeration. Other agars have their usable shelf lives extended by varying amounts. NanoLogix plates can be used for isolating microorganisms, total plate count, and for maintaining stock cultures. All of the Petri plates and BNP Petri kits NanoLogix produces are packaged in FlatPack packaging to ensure the longest useable shelf life, with most of the FlatPacks we produce undergoing a further electron-beam (e-beam) processing step to provide customers with the best product for their use with an extremely long shelf life.
NanoLogix®, Inc. is a biotechnology company specializing in live cell, rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical, national defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.
Stock Symbol: NNLX
06.27.14 11:15 Nanologix® News:
Nanologix granted an European patent
The European Patent Office has informed our London and US Patent Law firms that our European application for the BNP has been granted as a European Patent under the European Patent Convention. The 38 member states where this patent applies are: Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Turkey, Bulgaria, Czech Republic, Estonia, Slovakia, Slovenia, Hungary, Romania, Poland, Iceland, Lithuania, Latvia, Malta, Croatia, Norway, Former Yugoslav Republic of Macedonia, San Marino, Albania, and Serbia. With the EU Patent grant, NanoLogix is electing to file for national patent issuance in the majority of the covered countries with some exceptions. This BNP patent grant joins the NanoLogix portfolio of patents for the BNP granted in Japan and Russia, and when each member state patent is issued to NanoLogix will dramatically increase the number of granted patents in our portfolio.
06.04.14 05:05 Nanologix® News:
YSU business students learn by doing
NanoLogix is pleased to have been mentioned in a news update from Youngstown State University's Williamson College of Business Administration. The update focused upon the participation of seven area companies that worked with students on their Exporting Course projects for assessing international marketing potential. The assessments were performed utilizing a powerful marketing resource database available through the University and the State of Ohio. The management and staff of NanoLogix, as a member of the local business community and as a current exporter to a number of countries, view participation in educational projects such as this as part of their duty to that community. We are pleased to have been able to contribute to the education of students about to enter their business careers. more>>>
05.20.14 01:05 Nanologix® NewsWire: Nanologix Exhibits at ASM Annual Meeting in Boston and welcomes VP for Sales and Marketing Read more>>>
04.14.14 00:05 Nanologix® News: NanoLogix's new N-Assay rapid test discussed in article by Dr. Jonathan Faro in latest issue of Med Lab Observer Read more>>>
01.27.14 00:05 Nanologix® News: State of Ohio International Trade Assistance Center at YSU Assists NanoLogix with Foreign Distribution Agreements Read more>>>
12.04.13 12:02 Nanologix® News: Announces additional product offerings with E-Beam sterilization process - NanoLogix and Saudi Company To Work Together for Distribution of NanoLogix Products in the Arabian Gulf Region Read more>>>
06.21.13 NanoLogix BNP Instructional Video
06.11.13 02:31 Nanologix® News: US EPA and NanoLogix to Extend Agreement to 2015 Read more>>>
NanoLogix to Exhibit at Food Safety Summit in Baltimore and American Society for Microbiology Annual Meeting in Denver. Read more>>>
04.02.13 10:29 Nanologix® News:NanoLogix has been informed that they have been granted a patent in Japan for the Company's BNP detection technology. This is the first granted patent of seven patents pending for BNP throughout the world..
03.13.13 10:29 Nanologix® News:UTHealth researchers say more rapid test for Group B strep successful. Read more>>>
11.09.12 Nanologix® News: NanoLogix Subject of EPA Featured News article. Read more>>
6.13.12 Health News Texas: Texas Health Science Center-Huston instrumental in New NanoLogix Technology Read the article>>
SIGN UP FOR eNEWS
June 1, 2016:
NanoLogix update report
HUBBARD, OH--(Marketwired - Jun 1, 2016) - NanoLogix, Inc. ( OTC PINK : NNLX ), Due to ongoing shareholder requests NanoLogix is providing the following information as a short, non-comprehensive company update: Re: The earlier mentioned project to configure the N-Assay for one of the World's two largest medical technology companies has reached its final stages. NanoLogix has received two of three development funding payments from our client for the diagnostic kit configuration for the first target bacteria. After a 90-day development process at a third-party lab, we have received the antibody serum necessary to complete the kit configuration. What remains to be done are established proprietary steps to finalize what we will provide as finished N-Assay diagnostic kits. These steps are necessary in the case of the initial bacteria chosen by our client PRECISELY because there were no existent antibodies available commercially. The entire process should be complete within a month to the point where NanoLogix then will furnish a small number of the N-Assay kits to the client for their own in-house testing. At that time NanoLogix will invoice for the third tranche payment. Upon successful completion of testing by our client we anticipate two events to occur. These are: (1) purchase of kits (thousands) for the the first bacteria and (2) an additional, and expanded, development agreement from the client for configuration of the N-Assay for at least two additional target bacteria. NanoLogix is also in the final N-Assay configuration stages for detection of E-coli 0157 at the request of, and for use by, a US Federal Agency. A number of the assays will be sent to the agency within three weeks for their testing evaluation. We receive queries pertaining to the N-Assay asking why bacteria and yeast detection and identification testing results are not posted on our website. Regardless of how stunning in speed, accuracy, and sensitivity the N-Assay results are over ANY existing commercial tests, the simple answer is we are not permitted to post the results prior to publication of our research studies in a peer-reviewed scientific/medical journal. We have been informed that doing so would constitute publication ahead of the journal. Rather than risk jeopardizing journal publication to satisfy the desires of a few over the long term interests of many, we will refrain from posting of test results until journal publication.
Jan 11, 2016:
NanoLogix Announces Publication of a Study in Journal of Microbiology and Experimentation
HUBBARD, OH--(Marketwired - Jan 5, 2016) - NanoLogix, Inc. ( OTC PINK : NNLX ), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce publication in the Journal of Microbiology and Experimentation of a peer-reviewed study demonstrating dramatically extended shelf life and high-temperature durability of filled petri plates packed in NanoLogix-manufactured gas-charged FlatPacks. The study was performed by one of the world's largest and most prestigious Biomedical Research Centers.
Dec 21, 2015:
NanoLogix Announces Diagnostic Customization for Major Medical Device Company
NanoLogix, Inc. (OTC PINK: NNLX), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce that they have been contracted by one of the world's three largest global Medical Device manufacturers to customize the NanoLogix N-Assay, a unique modified ELISA diagnostic.
Oct 26, 2015:
NanoLogix BioTechnology announces:
1) The completion of N-Assay primary research by researchers in Houston, Texas. The research paper is being finalized for submission to a noted peer-reviewed journal. more>>>
July 1, 2015:
BNF Patent Granted - US Patent #9,068,216
The Company is pleased to announce the United States Patent and Trademark Office has granted U.S. Patent 9,068,216 on 30 June 2015 for: Methods and devices for rapid detection and identification of live microorganisms by aptamers and/or antibodies immobilized on permeable membranes more>>>
June 17, 2015:
Notification received from Peoples Republic of China for grant of FlatPack packaging patent
In early June, notification of "Grant Patent Right for Invention" was received from the China Patent intellectual Property Office in Beijing more>>>
June 16, 2015:
NanoLogix expands choices for order configuration
In order to better satisfy customer needs, effective July 1, 2015, NanoLogix will offer Flatpack petri plate configurations in Flatpacks of 20, 30, 40 and 50 plates in addition to the standard more>>>
May 04, 2015:
Rapid Tests for Fungal Infections The industry demands diagnostic tests that are fast, sensitive and easy to use more>>>